Pancreatic Cancer Research

ResearcherJiaxing UniversityActive in the last 2 years

Zhengwei Song

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5557-2298; OpenAlex author ID A5027263701. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
19
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 3 papers · 2025: 1 paper

Papers 8

  1. Reversing VTN deficiency inhibits the progression of pancreatic cancer and enhances sensitivity to anti-PD1 immunotherapy. Last author DOI 10.3389/fimmu.2025.1578870↗
  2. Apolipoprotein E is a prognostic factor for pancreatic cancer and associates with immune infiltration. Co-author DOI 10.1016/j.cyto.2024.156628↗
  3. Leveraging CAR macrophages targeting c-Met for precision immunotherapy in pancreatic cancer: insights from single-cell multi-omics. Co-author DOI 10.1186/s10020-024-00996-4↗
  4. MicroRNAs in pancreatic cancer drug resistance: mechanisms and therapeutic potential. Last author DOI 10.3389/fcell.2024.1499111↗
  5. LncRNA MALAT1 regulates METTL3-mediated PD-L1 expression and immune infiltrates in pancreatic cancer. Co-author DOI 10.3389/fonc.2022.1004212↗
  6. Clinical prognostic value of circulating tumor cells in the treatment of pancreatic cancer with gemcitabine chemotherapy. Co-author DOI 10.3892/etm.2021.10574↗
  7. AMP‑activated protein kinase family member 5 is an independent prognostic indicator of pancreatic adenocarcinoma: A study based on The Cancer Genome Atlas. Co-author DOI 10.3892/mmr.2020.11504↗
  8. Novel three‑lncRNA signature predicts survival in patients with pancreatic cancer. Co-author DOI 10.3892/or.2018.6761↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Fei Chen · 3 shared papers, 2020–2024 · strength 0.55
  2. Xiaoguang Wang · 2 shared papers, 2024–2025 · strength 0.51
  3. Xiaoguang Wang · 4 shared papers, 2018–2022 · strength 0.49
  4. Lingyu Hu · 2 shared papers, 2021–2025 · strength 0.39
  5. Fei Chen · 2 shared papers, 2018–2024 · strength 0.34
  6. Zhengxiang Zhong · 3 shared papers, 2018–2021 · strength 0.33
  7. Lingyu Hu · 1 shared paper, 2024 · strength 0.28
  8. Bin Yan Wu · 1 shared paper, 2024 · strength 0.28
  9. Bin Wu · 1 shared paper, 2024 · strength 0.26
  10. Jing Zhou · 1 shared paper, 2024 · strength 0.26
  11. Fangying Dong · 1 shared paper, 2024 · strength 0.26
  12. Siqi Zhao · 1 shared paper, 2025 · strength 0.26
  13. Haokai Xu · 2 shared papers, 2020–2021 · strength 0.25
  14. Xiaorong Liu · 1 shared paper, 2022 · strength 0.16
  15. Peter Wang · 1 shared paper, 2022 · strength 0.16
  16. Wei Chen · 1 shared paper, 2020 · strength 0.11
  17. Bin Wu · 1 shared paper, 2018 · strength 0.08
  18. Jun Gao · 1 shared paper, 2018 · strength 0.08
  19. Kaixuan Wang · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.